Argos Therapeutics, Inc.
ARGS
ARGS was delisted on the 24th of April, 2018.
30 hedge funds and large institutions have $34.7M invested in Argos Therapeutics, Inc. in 2014 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 9 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
6% less funds holding
Funds holding: 32 → 30 (-2)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
24% less capital invested
Capital invested by funds: $45.8M → $34.7M (-$11.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$188K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$171K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$148K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$138K |
| 5 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
+$99K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$982K |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$445K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$350K |
| 4 |
Morgan Stanley
New York
|
-$295K |
| 5 |
State Street
Boston,
Massachusetts
|
-$265K |
ARGS Hedge Fund Activity: Q2 2014 in Review
30 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Argos Therapeutics, Inc. (ARGS) for Q2 2014, worth a combined $34.7M — down 24% from $45.8M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ARGS and 7 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 8 added.
The largest buyer was Northern Trust, adding an estimated $188K. The largest seller was BlackRock Fund Advisors, exiting entirely with an estimated $982K sold.
- 30 institutional investors held Argos Therapeutics, Inc. (ARGS) as of Q2 2014, down from 32 in Q1 2014.
- Funds reported $34.7M of Argos Therapeutics, Inc. stock for Q2 2014, down 24% quarter-over-quarter.
- 7 funds opened new Argos Therapeutics, Inc. positions in Q2 2014 and 9 closed out, a net change of -2 holders.
- The largest Argos Therapeutics, Inc. buyer in Q2 2014 was Northern Trust, an estimated $188K added.
- The largest Argos Therapeutics, Inc. seller in Q2 2014 was BlackRock Fund Advisors, an estimated $982K sold.
Based on aggregated 13F filings for Q2 2014.